Johanna Friedl-Naderer

This profile gathers the share dealings of Johanna Friedl-Naderer across 2 companies, led by Dyne Therapeutics, Inc. and Vir Biotechnology, Inc. We count 17 filings; the first trade dates from 2 March 2022 and the latest from 8 September 2026.

The open-market record consists of 12 sales worth €84k, with no purchase. Outside the open market, there are 5 share grants. So far in 2026, the count stands at no purchases and 6 sales.

The newest entry dates from 8 September 2026: an open-market sale of €19k, in Dyne Therapeutics, Inc. Typically, a trade is published a median of 3 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.